Roche’s Elecsys Anti-SARS-CoV-2 S Receives the US FDA’s EUA to Detect Ab Against SARS-CoV-2 Spike Protein

 Roche’s Elecsys Anti-SARS-CoV-2 S Receives the US FDA’s EUA to Detect Ab Against SARS-CoV-2 Spike Protein

Roche’s Elecsys Anti-SARS-CoV-2 S Receives the US FDA’s EUA to Detect Ab Against SARS-CoV-2 Spike Protein

Shots:

  • The US FDA’s EUA follows the launch of the Elecsys Anti-SARS-CoV-2 S Ab test for markets accepting the CE Mark. The serology test can be used to measure the level of Abs in people who have been exposed to the SARS-CoV-2 virus
  • The test has both a high NPA of 99.98% and PPA of 96.6%, 15days or later after diagnosis with a PCR test. The test may help identify recovering patients who could potentially be serum & plasma donors for developing treatments for COVID-19
  • The test runs on Roche’s cobas e analyzers and is the latest addition to Roche’s diagnostic portfolio to help healthcare systems combat COVID-19 through testing in the laboratory and at the POC

Click here ­to­ read full press release/ article | Ref: Roche | Image: Pharma Live

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post